Brief: FDA Clears Sacituzumab Govitecan-Hziy For Two Indications In Adults With Triple-Negative Breast Cancer
24/06/2026 20:07
BRIEF-FDA Clears Sacituzumab Govitecan-Hziy For Two Indications In Adults With Triple-Negative Breast Cancer June 24 (Reuters) - FDA:
FDA APPROVES SACITUZUMAB GOVITECAN-HZIY AS MONOTHERAPY IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST-LINE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
Further company coverage: GILD.O
Recent news on Gilead Sciences,
See all newsAfrica CDC seeks $18 million in urgent support for Ebola drug trials in DRC
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: U.S. FDA Approves Trodelvy For First-Line Treatment Of Metastatic Triple-Negative Breast Cancer
Brief: FDA Clears Sacituzumab Govitecan-Hziy For Two Indications In Adults With Triple-Negative Breast Cancer
Focus: US provides Ebola treatment for outbreak in Congo, bringing trials closer